Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

INTEGRA Biosciences' reagent dispenser now supports SiLA-2 integration

INTEGRA Biosciences’ WELLJET reagent dispenser now supports API commands based on the SiLA-2 standardized communication protocol for lab automation. This new functionality will make it even easier to integrate the WELLJET into automated laboratory workflows, helping labs to enhance their productivity and reproducibility.

30 Jan 2025

Targeting MYCN and MDM2 offers new hope for cancer therapy

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

29 Jan 2025

Schrödinger selects Sapio Sciences to enhance in silico drug discovery from plasmid to structure

Sapio Sciences, the science-aware™ lab informatics platform, today announced that Schrödinger, a global leader in computational chemistry, has adopted the Sapio Platform to improve data management, enhance lab efficiency, and accelerate the discovery of novel molecules.

From Sapio Sciences 29 Jan 2025

Discovery could contribute to the development of new drugs for transthyretin amyloidosis

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion.

29 Jan 2025

Breakthrough gene discovery offers new hope for medulloblastoma therapy

Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

24 Jan 2025

Research could lead to better medicines and new tools in synthetic biology

Proteins are life's engines, powering processes like muscle movement, vision, and chemical reactions. Their environments-water, lipid membranes, or other condensed phases-are critical to their function, shaping their structure and interactions.

24 Jan 2025

Revvity ignites scientific breakthroughs at SLAS2025

Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis.

From Revvity 24 Jan 2025

New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

23 Jan 2025

New method enables simultaneous multi-color imaging with bioluminescent proteins

Imaging live cells with fluorescent proteins has long been a crucial technique for understanding cellular behavior. While bioluminescent proteins offer several advantages over fluorescent proteins, the limited availability of color variants has made it difficult to observe multiple targets simultaneously.

23 Jan 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Exploring the role of confocal-based high-content imaging in advancing core facilities

In this interview, NewsMedical speaks with Esther Kieserman and Arvonn Tully from Yokogawa Life Science about how confocal-based high-content imaging is advancing core facility research and improving data reliability.

From Yokogawa Life Science 20 Jan 2025

New discovery in HIV vaccine response reveals surprising antibody behavior

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection.

17 Jan 2025

Grifols receives grant for early Parkinson's disease biomarker discovery

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) many years before clinical diagnosis.

15 Jan 2025

Panakeia launches AI-driven PANProfiler Colon for rapid cancer profiling

Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces the launch of PANProfiler Colon, an AI-driven software solution for profiling of Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) entirely digitally and directly from Hematoxylin and Eosin (H&E)-stained images of colon cancer tissue samples.

15 Jan 2025

CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech.

From CN Bio 15 Jan 2025

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.

From Enhanc3D Genomics 15 Jan 2025

Uncovering the neurobiological mechanisms of delta opioid receptor agonists

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, including slow action and adverse effects with long-term use. This underscores the urgent need for novel, rapidly-acting therapeutic agents with minimal side effects.

15 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Breakthrough in chemical synthesis expands possibilities for ketones and esters

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

10 Jan 2025

Developing and refining muscle atrophy models for drug discovery

With the intensification of global population aging, muscle atrophy, characterized by the loss of muscle mass and function, has become an important health issue affecting the elderly. Researchers have widely used various animal and cellular models to gain a deeper understanding of the pathophysiological mechanisms of muscle atrophy and develop effective treatment strategies.

9 Jan 2025

Drug Discovery News and Research

Further Reading

INTEGRA Biosciences' reagent dispenser now supports SiLA-2 integration

Targeting MYCN and MDM2 offers new hope for cancer therapy

Schrödinger selects Sapio Sciences to enhance in silico drug discovery from plasmid to structure

Discovery could contribute to the development of new drugs for transthyretin amyloidosis

Breakthrough gene discovery offers new hope for medulloblastoma therapy

Research could lead to better medicines and new tools in synthetic biology

Revvity ignites scientific breakthroughs at SLAS2025

New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

New method enables simultaneous multi-color imaging with bioluminescent proteins

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Exploring the role of confocal-based high-content imaging in advancing core facilities

New discovery in HIV vaccine response reveals surprising antibody behavior

Grifols receives grant for early Parkinson's disease biomarker discovery

Panakeia launches AI-driven PANProfiler Colon for rapid cancer profiling

CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Uncovering the neurobiological mechanisms of delta opioid receptor agonists

Menarini Group signs licensing deal with Insilico for promising cancer treatment

Breakthrough in chemical synthesis expands possibilities for ketones and esters

Developing and refining muscle atrophy models for drug discovery

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®